Chilblains after galcanezumab for chronic migraine prevention: A case report
Abstract
Background Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) are effective migraine prophylactics but real-world safety data is still emerging. This is the first case of chilblains associated with galcanezumab. Case A 50-year-old female commenced galcanezumab for migraine prophylaxis. She tolerated the loading dose well. Ten days after her second dose, she developed multiple skin lesions, fluctuating distal cyanosis and polyarthralgia in both hands. Rheumatologists confirmed a diagnosis of chilblains temporally related to the CGRP mAb. Galcanezumab was subsequently ceased with full clinical recovery. There was no clinical or serological evidence of an underlying autoimmune condition. Conclusion This case demonstrates a previously unreported reaction temporally associated with galcanezumab. We hypothesise herein a mechanism of biological plausibility for this reaction based on the drug's mechanism of action. Vigilance is required in monitoring for potential adverse events. Further research is required into risk factors for such presentations. Graphical abstract This is a visual representation of the abstract.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
- Bioaccessibility and bioavailability of phenolic compounds
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
- Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.